Mark N. Stein

11.7k citations

243 papers · 5.8k indexed · 2 hit papers · h-index 40

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
Cancer Research top 1%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics

Papers in

Oncology 134
- Cancer Immunotherapy and Biomarkers 64
- Cancer Treatment and Pharmacology 23
Pulmonary and Respiratory Medicine 138
- Prostate Cancer Treatment and Research 75
- Renal cell carcinoma treatment 41

Co-authors: Robert S. DiPaola Eileen White Susan Goodin Kevin Bray Grace L. Lu‐Yao Charles G. Drake Yu‐Hsuan Joni Shao Simantini Eddy
Journals: Journal of Clinical Oncology (111 papers)Clinical Cancer Research (9 papers)Cancer Research (8 papers)Annals of Oncology (8 papers)Investigational New Drugs (7 papers)
Partner nations: United States France United Kingdom

In The Last Decade

Mark N. Stein

232 papers receiving 5.8k citations

Hit Papers

align trajectories log scale

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial 2021 · 170 citations

Peers

Countries citing papers authored by Mark N. Stein

Since Specialization

Citations

This map shows the geographic impact of Mark N. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Stein more than expected).

Fields of papers citing papers by Mark N. Stein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark N. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Stein. The network helps show where Mark N. Stein may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark N. Stein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark N. Stein Line = papers co-authored together Mark N. Stein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4). Journal of Clinical Oncology ·Noah M. Hahn, Marianna Zahurak, Hristos Z. Kaimakliotis, Timothy A. Masterson, Nabil Adra, David YT Chen, Alexander Kutikov, Daniel M. Geynisman, Woodson Smelser, Melissa A. Reimers, Christopher B. Anderson, Mark N. Stein, Alexander S. Baras, Gabriela Colocho, Deborah E. Schwartz, David J. McConkey, Sunil Patel, Bilal Rahim, Michael A. O’Donnell, Max Kates	2025	0
2	A phase 2, randomized, open-label study of gemcitabine/cisplatin plus cemiplimab (REGN2810, anti-PD-1) with or without fianlimab (REGN3767, anti-LAG-3) for organ preservation in patients with localized muscle-invasive bladder cancer (NeoSTOP-IT). Journal of Clinical Oncology ·Alexander Z. Wei, Basil Bakir, Andrew T. Lenis, Christopher B. Anderson, Karie Runcie, G. Joel DeCastro, Samuel S Pan, Michael M. Shen, James M. McKiernan, Mark N. Stein	2025	0
3	A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology ·Bilal A. Siddiqui, Benedito A. Carneiro, Mark N. Stein, Jingsong Zhang, William Kevin Kelly, David R. Wise, Kai Tsao, Gerald S. Falchook, Przemyslaw Twardowski, Xīn Gào, Joseph W. Kim, Edward P. Gelmann, Pradeep Thanigaimani, Fang Fang, Frank Seebach, Israel Lowy, Matthew Ingham, Michael D. Kinnaman, Sabina Sandigursky, Elizabeth Miller	2025	1
4	Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) Journal for ImmunoTherapy of Cancer ·Michael B. Atkins, Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein, Jeffrey A. Sosman, Robert Alter, Elizabeth R. Plimack, Moshe Chaim Ornstein, Michael E. Hurwitz, David Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J. Wu, David A. Braun, David J. Einstein, Paul J. Catalano, Hans J. Hammers	2023	19
5	764 A phase 1, first-in-human (FIH), open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors SHILAP Revista de lepidopterología ·Manojkumar Bupathi, Judy S. Wang, Siwen Hu‐Lieskovan, Sarina A. Piha‐Paul, Bartosz Chmielowski, Benjamin Garmezy, Yana G. Najjar, Mark N. Stein, Li Yao, Jitendra Kanodia, Raphael Clynes, Patricia McGovern, Benjamin J. Thompson	2023	3
6	Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial The Lancet ·Christopher W. Ryan, Catherine M. Tangen, Elisabeth I. Heath, Mark N. Stein, Maxwell V. Meng, Ajjai Alva, Sumanta K. Pal, Igor Puzanov, Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian Shuch, Ian M. Thompson, Primo N. Lara	2023	21
7	ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study The Oncologist ·Mark N. Stein, Lawrence Fong, Ronald Tutrone, Anthony Mega, Elaine T. Lam, Megan Parsi, Surya Vangala, Andres Gutierrez, Naomi B. Haas	2022	28
8	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era Cancer Medicine ·Isaac Yi Kim, Thomas L. Jang, Sinae Kim, David Y. Lee, Daniel D Kim, Eric A. Singer, Saum Ghodoussipour, Mark N. Stein, Monish Aron, Marc Dall’Era	2021	4
9	Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer Cancer Medicine ·Xiang‐Lin Tan, E Jian‐Yu, Yong Lin, Timothy R. Rebbeck, Shou‐En Lu, Mingyi Shang, William Kevin Kelly, Anthony V. D’Amico, Mark N. Stein, Lanjing Zhang, Thomas L. Jang, Isaac Yi Kim, Kitaw Demissie, Anna C. Ferrari, Grace L. Lu‐Yao	2020	23
10	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma Clinical Cancer Research ·Naomi B. Haas, Leonard J. Appleman, Mark N. Stein, Maryann Redlinger, Melissa Wilks, Xiaowei Xu, Angelique Onorati, Anusha Kalavacharla, Tae Hyong Kim, Chao Jie Zhen, Sabah Kadri, Jeremy P. Segal, Phyllis A. Gimotty, Lisa E. Davis, Ravi K. Amaravadi	2019	112
11	ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS Neuro-Oncology ·Rohinton S. Tarapore, Sachin R. Jhawar, Mark N. Stein, B. Haffty, Andrew Zloza, Sabine Mueller, J Zhang, Francesca Amoroso, Ian G. Mills, Wolfgang Oster, Joseph D. Allen	2018	1
12	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer Clinical Cancer Research ·Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary‐Ellen Taplin, James S. Babb, Ethan Barnett, Alejandro Gómez-Pinillos, Xiaomei Liu, Dirk F. Moore, R. P. DiPaola, Tomasz M. Beer	2018	52
13	Trends in active surveillance for very low‐risk prostate cancer: do guidelines influence modern practice? Cancer Medicine ·Rahul R. Parikh, Sinae Kim, Mark N. Stein, Bruce G. Haffty, Isaac Yi Kim, Sharad Goyal	2017	20
14	A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors Investigational New Drugs ·Janice M. Mehnert, Gerald M. Edelman, Mark N. Stein, Heather Camisa, Joanne Lager, Jean-François Dedieu, Anne-Frédérique Ghuysen, Jyoti Sharma, Li Liu, Patricia LoRusso	2017	11
15	BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Clinical Cancer Research ·Nitu Bansal, Monica Bartucci, Shamila Yusuff, Stephani A. Davis, Kathleen Flaherty, Eric Huselid, Michele Patrizii, Daniel M. Jones, Liangxian Cao, Nadiya Sydorenko, Young‐Choon Moon, H. Zhong, Daniel Medina, John E. Kerrigan, Mark N. Stein, Isaac Yi Kim, Thomas W. Davis, Robert S. DiPaola, Joseph Bertino, Hatem E. Sabaawy	2016	49
16	A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study Investigational New Drugs ·Manish Thakur, Lance K. Heilbrun, Shijie Sheng, Mark N. Stein, Glenn Liu, Emmanuel S. Antonarakis, Ulka N. Vaishampayan, Sijana H. Dzinic, Xiaohua Li, Stacy Freeman, Daryn Smith, Elisabeth I. Heath	2015	43
17	Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial Clinical Cancer Research ·Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C. Bendell, Andrés Cervantes, Mark N. Stein, Irene Braña, Desamparados Roda, Brian B. Haines, Theresa Zhang, Christopher Winter, Sharda Jha, Youyuan Xu, Jason P. Frazier, Richard A. Klinghoffer, Ann Leighton-Swayze, Yang Song, Scot Ebbinghaus, José Baselga	2014	48
18	A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors Molecular Cancer Therapeutics ·Jordi Rodón, Amita Patnaik, Mark N. Stein, Anthony W. Tolcher, Chee M. Ng, Cinara Dias, Gérard Greig, Stanley Frankel, Razelle Kurzrock, Eric Rubin	2007	10
19	A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC). Molecular Cancer Therapeutics ·Robert W. Ross, Ramaprasad Srinivasan, Ulka N. Vaishampayan, Ronald M. Bukowski, Jonathan E. Rosenberg, Peter D. Eisenberg, Theodore F. Logan, Sandhya Srinivas, Mark N. Stein, Thomas Mueller, Harold Keer	2007	7
20	Antibody-dependent cell cytotoxicity to breast cancer targets despite inhibitory KIR signaling. PubMed ·Mark N. Stein, James Shin, Oksana Gudzowaty, Andrew M. Bernstein, Johnson M. Liu	2006	12

About Mark N. Stein

Mark N. Stein is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 243 papers that have together received 5.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (75 papers), Cancer Immunotherapy and Biomarkers (64 papers), Renal cell carcinoma treatment (41 papers), Bladder and Urothelial Cancer Treatments (31 papers), Cancer Genomics and Diagnostics (25 papers), Cancer Treatment and Pharmacology (23 papers), Immunotherapy and Immune Responses (23 papers) and Radiopharmaceutical Chemistry and Applications (22 papers). The work is most often cited by research in Oncology (2.5k citations), Cancer Research (1.3k citations), Pulmonary and Respiratory Medicine (2.1k citations), Immunology (880 citations) and Molecular Biology (2.3k citations). Mark N. Stein has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Robert S. DiPaola, Eileen White, Susan Goodin, Kevin Bray, Grace L. Lu‐Yao, Charles G. Drake, Yu‐Hsuan Joni Shao, Simantini Eddy, Dmitri Dvorzhinski and Amit Mehta. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Research, Annals of Oncology and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact